Carol Christopher
Christopher Caires
David Crean
David H. Crean, Ph.D is a Managing Director at Objective Capital Partners where he leads the firm’s life science investment banking transactions. Dr. Crean has in excess of 20 years of life sciences R&D and corporate development transactional experience in the pharmaceutical industry where he was responsible for leading mergers, acquisitions, licensing and collaborations, and establishing corporate strategy. David’s transaction experience in the life sciences sector includes sell-side, buy-side, licensing and capital raising activities. He has supported company and client engagements in both U.S. domestic and foreign transactions including Japan, China and Europe.
Prior to joining Objective Capital Partners, Dr. Crean served over 20 years in specialty pharmaceuticals; namely at Allergan (NYSE:AGN) and Aqua Pharmaceuticals, a private equity-backed company, prior to being sold to Almirall, SA. (BME:ALM). Dr. Crean has led transaction execution in a wide range of specialty areas including aesthetic and therapeutic dermatology, OTC skin care, neurological disorders / CNS, pain, inflammation, ophthalmology, oncology and diagnostics/ detection. His corporate pharmaceutical experience spans research and development expertise in small molecules, biologics, prescription drugs, OTC products and medical devices.
Dr. Crean’s pharmaceutical and biotechnology leadership experience includes serving in key leadership roles in the development and/or growth of many commercial portfolios including: BOTOX, LUMIGAN, JUVEDERM, LATISSE, ACZONE, TAZORAC, MONODOX, FLUOROPLEX, XOLEGEL and VERDESO. Concurrent with Objective Capital, Dr. Crean serves as a strategic business advisor for several life science companies, is an active member on BIOCOM’s Capital Development Committee and BIO International 2017 Partnering Committee and a contributing member on the Membership & Program Committees for the Association for Corporate Growth (ACG) in San Diego.
Dr. Crean holds a Masters of Business Administration Degree with a finance concentration from Pepperdine University School of Management. Additionally, he holds a Doctorate of Philosophy Degree in Biophysics and a Masters of Science Degree in Oncology from the State University of New York at Buffalo. Dr. Crean also earned a Bachelor of Science Degree in Biology from Canisius College.
Dr. Crean holds FINRA Series 79 and Series 63 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.
Hasti Nazem
Hasti is part of the founding team of Kindra, leading product development and education. Kindra is developing innovative estrogen-free solutions targeting the top pain points of the 34+ symptoms of menopause. With nearly 10 years of experience at the intersection of life sciences, health and wellness, and consumer brand building, Hasti integrates targeted product formulation development with cutting edge technical advancements. Her deep scientific communications experience helps to empower consumers to better understand their health, and bridge gaps often overlooked in women's health. Hasti's work has been featured in has been featured in The New York Times, Forbes.com, (O) Oprah Magazine, Harper's Bazaar, Women's Health Magazine, and in healthcare public affairs and pharmaceutical trade association publications.
Beauty Spotlights Videos
Jay Tiesman
Dr. Jay Tiesman is a Principal Scientist in the Global Biotechnology Division of The Procter & Gamble Company in Cincinnati, Ohio, USA. He is the Genomics Group Leader and a Corporate Technology Entrepreneur charged with helping to identify novel biotechnology innovations worldwide to address key needs for P&G. Since joining P&G in 1993, he has been actively involved in developing genomics capabilities within the Company. He has been particularly interested in the use of genomics to gain insight into epithelial cell biology.
Before joining P&G, he completed postdoctoral training in the laboratory of Dr. Charlie Hart at ZymoGenetics, Inc. in Seattle, Washington. At ZymoGenetics, he pursued research in the field of growth factor signal transduction associated with wound healing and tissue remodeling. He obtained his Ph.D. in Pathology from the University of Nebraska Medical Center in Omaha, Nebraska. In Omaha, he worked in the Laboratory of Dr. Angie Rizzino at the Eppley Cancer Institute, delineating the roles and impact of growth factors on embryonic development. Before joining Dr. Rizzino, he obtained Bachelor degrees in Philosophy and Biology at Creighton University in Omaha.
Dr. Tiesman was an early adopter of microarray technology, having worked in the field since 1997. He is an acknowledged microarray expert and has published over 35 articles, two of which have earned Publication of the Year honors. He also speaks extensively at international meetings on the topic of microarray experimental design and is listed on over 85 presentations. He collaborates extensively with scientists in academia and the biotechnology industry and is a member of several academic/governmental/industrial organizations, including the Association of Biomedical Resource Facilities Microarray Research Group (ABRF-MARG), the Association of Molecular Pathology (AMP), and the Society for Investigative Dermatology (SID); as well as the Scientific Advisory Board of NuGEN Technologies, Inc.
Allison Krebs Bensch
Allison Krebs-Bensch, a graduate of Vanderbilt University, has been intrinsically involved in her family’s pharmaceutical business, US Pharmaceutical Corporation, since graduating. Rolling up her sleeves, Allison dove into learning every aspect of the business from Sales to R & D, before eventually taking over the responsibilities of CEO.
Allison’s accomplishments include being listed as an inventor on patents for Improved Toleration of Iron Supplement Compositions. Additionally, she has developed, progressive & pending, patented formulations utilizing new probiotic strains for various applications of use. Most recently, she has co-founded and is CEO of a start-up probiotic skin care company, BeBe and Bella. This company specializes in delivering probiotics and their fermented filtrates, both orally and topically, for improved natural beauty. As co-founder, Allison has been invited to be a Speaker at several symposiums related to the science behind probiotics.